12
BioTOPics 46 | September 2013
BioTOP-Report
Metanomics Health GmbH
Metanomics Health – a BASF Group compa-
ny – applies comprehensive Metabolite Pro-
filing (metabolomics) with biomedical data
interpretation. Metabolite Profiling is
defined as the parallel analysis of multiple
endogenous and xenobiotic metabolites in
biological systems. The core expertise of
Metanomics Health resides in discovery and
validation of biomarkers.
Technologies
k
Metabolite profiling platform with more
than 75 GC-MS and LC-MS/MS instru-
ments
k
Wide metabolite
coverage via combina-
tion of unbiased and targeted platforms
k
Unique tox mode of action prediction
through MetaMap
®
Tox database
k
Excellence in systems correlation analy-
sis of complex gene function relation-
ships
Major R&D-Topics
In cooperation with academic institutes and
clinical experts Metanomics Health is run-
ning a large-scale diagnostic biomarker pro-
gram. Areas include metabolic syndrome,
heart failure, prostate cancer and multiple
sclerosis to mention a few.
Market Segments
Metanomics Health provides its services to
pharmaceutical, diagnostics and nutrition
companies. Technology applications include:
k
Mechanism of action studies
k
Mechanism of toxicity studies
k
Translational and clinical biomarker
development (e.g. PK/PD, patient stratifi-
cation, efficacy and safety markers)
k
Companion diagnostic development
k
Cell culture & bioprocess optimization
Address
Metanomics Health GmbH
Tegeler Weg 33
10589 Berlin · Germany
Contact
Dr. Tim Bölke · Managing Director
Phone +49 30 34807 400
Fax
+49 30 34807 401
company.info@metanomics-health.de
www.metanomics-health.de
nanoPET Pharma GmbH
nanoPET is a biopharmaceutical company
specialized on R&D, manufacturing and mar-
keting of innovative drug substances for
Diagnostic Imaging. We focus on relevant
cardiovascular, oncological and neurological
indications as well as on regenerative medi-
cine. Nanotechnology is a key element of our
business. We operate in three major areas.
The first nanoparticular tracers for clini-
cal PET: nanoPET prepares the clinical devel-
opment of its patented technology platform:
inorganic nanoparticular tracers for cell- and
molecular-specific positron emission tomog-
raphy (PET).
Viscover™ imaging agents – a landmark
in small animal imaging: As animal imag-
ing is rapidly gaining relevance in pharma-
ceutical research, we are delighted to offer
you an exciting portfolio of specialized pre-
clinical imaging agents covering the princi-
pal imaging modalities (MRI, CT, Ultrasound,
Optical Imaging, SPECT & PET). Get a
detailed insight into our product portfolio
and download a free copy of our imaging
guide on www.viscover.com
Consulting and Service tailored to your
needs: As a technology
and service provider,
we offer our expertise to biopharmaceutical
companies and imaging equipment manu-
facturers. Our customers benefit from the
long-standing industry expertise our team
has attained in the pharmaceutical
research & development.
Address
nanoPET Pharma GmbH
Robert-Koch-Platz 4
10115 Berlin · Germany
Contact
Dr. Andreas Briel · CEO
Phone +49 30 890 49740
imaging@nanopet-pharma.com
www.nanopet-pharma.com
13
BioTOPics 46 | September 2013
BioTOP-Report
ORGANOBALANCE GmbH
Exploring and managing microbial
biodiversity
ORGANOBALANCE explores the potential of
probiotic bacteria and yeasts for new prod-
uct developments in food, feed, personal
care, and for the pharmaceutical industry or
the production of fine chemicals. From a
large collection of microorganisms, specific
strains are selected to e.g. inactivate patho-
gens, produce new bioactives, neutralize
malodorous or toxic substances and synthe-
size high titers of valuable compounds.
ORGANOBALANCE draws on natural
resources, which are gathered in the compa-
ny-owned collection of 8000+ microbial
strains, mostly originating from foodstuffs.
ORGANOBALANCE uses its OASSYS
®
bioas-
says for highly efficient screenings. The plat-
form allows to quickly identify the most suit-
able strains from the microbial collection for
targeted applications.
ORGANOBALANCE has a broad expertise in
the field of yeast metabolic engineering.
This includes designing and developing new
production strains for industrial biotechnol-
ogy applications. Specific strains of Saccha-
romyces cerevisiae, which carry engineered
biosynthesis pathways for the environmen-
tally friendly production of carboxylic acids,
terpenoids, steroids and other lipid com-
pounds are available.
ORGANOBALANCE works in collaboration
with partners and grants licenses for own
product developments.
Address
ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin · Germany
Contact
Dr. Christine Lang · CEO
Phone +49 30 46307200
Fax
+49 30 46307210
info@organobalance.com
www.organobalance.com
Our experience is your success!
The German Pharmaceutical Industry Association (BPI –
Bundesverband der Pharmazeutischen Industrie e.V.)
consists of approximately 240 pharmaceutical companies.
These include not only the classic pharmaceutical firms
and service-providers, but also biotechnology companies
and manufacturers of medical devices.
All of our members use our association as a platform for
information and communication to develop collaborative
responses to the diverse challenges they face.
Our team consists of highly qualified experts in all fields
which are necessary to generate a sustainable benefit for
pharmaceutical companies, e.g. market access, regula-
tory affairs, law, biotechnology and political affairs.
Interested in being a member? Feel free to contact us!
info@bpi.de · www.bpi.de · Phone: +49 – 30 – 27909 – 0
Start Up-Companies are eligible for reduced member-
ship fees while having the possibility to participate in
all activities of our association.